Compare Smith & Nephew plc (SNN) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Health Care Select Sector SPDR Fund — how do they compare? Smith & Nephew plc trades at $30.23 (market cap $12.54B), while Health Care Select Sector SPDR Fund trades at $168.74. The key difference: Smith & Nephew plc pays a 2.65% dividend while Health Care Select Sector SPDR Fund pays none, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SNN | XLV | |
|---|---|---|
Market Cap | $12.54B | — |
Sector | Health | — |
52-Week High | $38.70 | $168.44 |
52-Week Low | $28.73 | $131.16 |
Enterprise Value | $15.57B | — |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
XLV, the Health Care Select Sector SPDR ETF, trades at $168.44 with a neutral daily change. Technical indicators show a bullish trend from moving averages but oscillators are neutral, with the 6-day RSI at 86.78 suggesting overbought conditions. The fund's low 0.08% expense ratio and defensive healthcare sector exposure attract steady inflows amid market volatility, as highlighted by recent ETF flow reports.
The outlook for XLV is cautiously optimistic, supported by defensive demand and strong sector earnings. Key opportunities include diversification benefits and cost efficiency, while risks involve sector-specific regulatory pressures and broader economic sensitivity. Investors should weigh the ETF's stability against potential growth limitations in a concentrated portfolio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
